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Abstract
Aim
To examine whether elevated anxiety and/or depressive symptoms are related to all-cause
mortality in people with Type 2 diabetes, not using insulin.
Methods
948 participants in the community-wide Nord-Trøndelag Health Survey conducted during
1995–97 completed the Hospital Anxiety and Depression Scale with subscales of anxiety
(HADS-A) and depression (HADS-D). Elevated symptoms were defined as HADS-A or
HADS-D8. Participants with type 2 diabetes, not using insulin, were followed until Novem-
ber 21, 2012 or death. Cox regression analyses were used to estimate associations
between baseline elevated anxiety symptoms, elevated depressive symptoms and mortal-
ity, adjusting for sociodemographic factors, HbA1c, cardiovascular disease and microvascu-
lar complications.
Results
At baseline, 8% (n = 77/948) reported elevated anxiety symptoms, 9% (n = 87/948) elevated
depressive symptoms and 10% (n = 93/948) reported both. After a mean follow-up of 12
years (SD 5.1, range 0–17), 541 participants (57%) had died. Participants with elevated
anxiety symptoms only had a decreased mortality risk (unadjusted HR 0.66, 95% CI 0.46–
0.96). Adjustment for HbA1c attenuated this relation (HR 0.73, 95% CI 0.50–1.07). Those
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with elevated depression symptoms alone had an increased mortality risk (fully adjusted
model HR 1.39, 95% CI 1.05–1.84). Having both elevated anxiety and depressive symp-
toms was not associated with increased mortality risk (adjusted HR 1.30, 95% CI 0.96–
1.74).
Conclusions
Elevated depressive symptoms were associated with excess mortality risk in people with
Type 2 diabetes not using insulin. No significant association with mortality was found
among people with elevated anxiety symptoms. Having both elevated anxiety and depres-
sive symptoms was not associated with mortality. The hypothesis that elevated levels of
anxiety symptoms leads to behavior that counteracts the adverse health effects of Type 2
diabetes needs further investigation.
Introduction
People with Type 2 diabetes are more likely to experience elevated depression and/or anxiety
symptoms or an anxiety disorder, than people without diabetes [1–3]. While depression affects
approximately one in five individuals with Type 2 diabetes [2], generalized anxiety disorder
and elevated anxiety symptoms have been reported to be present in 14% and 40%, respectively
[4].
Depression was found to be associated with a higher risk of adverse diabetes outcomes and
higher mortality rates [5]. Depression in diabetes is associated with suboptimal HbA1c levels
[6], development of vascular complications [7] and increased all-cause and cardiovascular
mortality [8]. However, less is known about the health risks imposed by elevated anxiety symp-
toms. A meta-analysis including 11 cross-sectional studies found that anxiety disorders, but
not elevated anxiety symptoms, were associated with hyperglycemia [9]. Unfortunately, most
of the included studies had a small sample size (9 studies,< n = 125) or included clinical sam-
ples only, and only one study included only patients with Type 2 diabetes [9]. More recent
cross-sectional studies examining the association between anxiety and the presence of diabetes
complications have found mixed results [10–12]. Longitudinal studies focusing on the relation
between anxiety and health outcomes are still lacking in people with Type 2 diabetes.
There is evidence from longitudinal cardiovascular studies that having symptoms of both
anxiety and depression predicts poor health outcomes [13–15]. It is therefore relevant to test
whether having not only elevated depression symptoms, but also other emotional problems
such as elevated anxiety symptoms, are associated with risk of mortality Furthermore, it is
unclear whether data that are collected early in the course of the disease (i.e. before insulin
therapy is initiated) are associated with increased mortality risk. Therefore, we aimed to
include a sample of people with less severe diabetes (i.e. not using insulin) and also report on
the associations with both anxiety and depression. Moreover, the Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition (DSM-5) has now added a new specification to the
diagnosis of major depressive disorder: “with anxious distress”. The aim of the present study
was to examine whether elevated anxiety symptoms, elevated depressive symptoms, or both,
are associated with increased risk of mortality during 17 years follow up in insulin naïve people
with Type 2 diabetes.
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Material and Methods
Study sample
The Second Nord Trøndelag Health Study (HUNT2) was conducted in one large Norwegian
county during 1995–1997, inviting all residents aged 20 years. The population is ethnically
homogenous, with only a small percentage (3%) of people of non-Caucasian origin [16]. In
total 93,898 persons were invited, 69% filled out the first general questionnaire on health
behaviours, health status and demographics. A total of 1972 (3%) persons answered affirma-
tively on the question “Do you have or have you had diabetes?” Participants who reported to
have diabetes received an additional diabetes-specific questionnaire and were invited to a fol-
low-up visit with collection of a fasting blood sample to determine diabetes type (attendance
rate: 75%). Participants were classified as having type 1 or type 2 diabetes based on a combina-
tion of three factors: (1) measures of fasting C-peptide and glutamic acid decarboxylase anti-
bodies (anti-GAD), (2) fasting glucose levels [16]. In the diabetes-specific questionnaire,
participants were asked about diabetes treatment. Those who answered that they did not use
insulin were classified as respondents with insulin-naïve Type 2 diabetes. For participants who
did not answer the treatment question (medication use at baseline), we retrieved information
on the prescription of insulin (Anatomical Therapeutic Chemical code A10A) from the Norwe-
gian Prescription Database (NorPD). These data showed that 126 participants who had not
answered the treatment question did not use insulin. This registry includes individual prescrip-
tion data from all Norwegian residents, with complete data from January 1, 2004. We linked
data from HUNT2 to data from the NorPD using the 11-digit personal identification number
unique to each Norwegian resident.
Of 1124 participants with diabetes who were not treated with insulin, 948 completed the
Hospital Anxiety and Depression Scale (HADS) with valid answers on the anxiety (HADS-A)
and the HADS depression (HADS-D) subscale (responded on 5 or more questions on each
subscale) (Fig 1); the analyses in the present study are based on this group.
Assessment of anxiety and depressive symptoms
The HADS was used to assess symptoms of anxiety and depression [17]. This self-report
measure was originally designed for symptom screening in hospital settings using cognitive
symptoms of depression and anxiety. Somatic symptoms of depression were not used, as
these can also be attributed to a somatic illness. This was done to reduce the likelihood of
false-positive cases among individuals with somatic diseases [17]. The HADS anxiety and
depression subscales include seven questions on general symptoms of anxiety and depres-
sion, respectively, during the past week. Each item is scored on a Likert scale ranging from 0
to 3; yielding a maximum score of 21. Higher scores indicate a higher symptom load. The
HADS-A and HADS-D have previously been shown to have good psychometric properties in
the HUNT2 study [18]. HADS-A and HADS-D were used as dichotomous variables with a
cut-off level of8 for caseness of anxiety or depression. This cut-off level has been shown to
yield a sensitivity and specificity of about 0.8 on each subscale. To enhance the specificity of
identifying anxiety or depression, a cut-off point of 11 is also used [19]. We imputed missing
items for individuals who had responded to only five or six of the HADS-A or HADS-D ques-
tions [18]. This was done by multiplying the obtained score by 7/5 if five of the seven ques-
tions were answered and by 7/6 if six questions were answered. Such missing substitution
was done for 23.5% of participants for the HADS-A scale and 8.5% for HADS-D scale. Some
15% and 10% answered fewer than five questions on HADS-A and HADS-D, respectively,
and were excluded.
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Potential demographic and clinical confounders
In the general baseline questionnaire participants were asked about age, gender and their level
of education. In the analyses education was categorized as a low (<10 years) or high (10
years) level. Living alone was categorized as yes/no. Questions related to cardiovascular disease
included having a history of angina pectoris, myocardial infarction or stroke. These three con-
ditions were combined into a composite measure of any cardiovascular disease (yes/no). The
diabetes-specific questionnaire included a question about the presence of eye problems due to
diabetes. Participants reported having diabetes received tubes for collecting three consecutive
first-morning urine samples, which were analyzed for albumin and creatinine levels [16]. We
defined microalbuminuria as an albumin-to-creatinine ratio exceeding 3.0 mg/mmol in at least
two of the three urine samples [20]. Eye problems due to diabetes and microalbuminuria were
combined into a composite measure of any microvascular complication (yes/no). During the
follow-up visit, an EDTA (ethylenediaminetetraacetic acid) whole-blood sample was drawn for
analyzing glycated hemoglobin (HbA1c). HbA1c measurements were reported in International
Federation of Clinical Chemistry units (mmol/mol) in addition to derived NGSP units (%)
(http://www.ngsp.org/convert1.asp).
Fig 1. Study flowchart for the cohort recruited from HUNT2 (1995–1997). a Self-reported diabetes,
verified as Type 2 diabetes and have answered not to use insulin (n = 783); self-reported diabetes, who have
answered not to use insulin (n = 215); self-reported diabetes, not answering treatment question but verified as
not using insulin in the Norwegian Prescription Data base (n = 126). b Completed fewer than five questions on
the HADS anxiety (HADS-A) and/or depression (HADS-D) subscales.
doi:10.1371/journal.pone.0160861.g001
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Follow-up mortality data
Information on date of death was obtained from the Norwegian Population Registry. We fol-
lowed participants from the baseline examination to time of death (end point) or November
21, 2012 (end of the follow-up period), whichever came first.
Ethics
The Mid Norway Regional Committee for Medical and Health Research Ethics approved the
study protocol (2011/1157), and the Norwegian Social Science Data Services approved merging
the HUNT-2 data and the NorPD registry.
Statistical analyses
All analyses were performed using IBM SPSS Statistics (version 19.0), Somers, NY, USA. A
p-value<0.05 was considered statistically significant. Using earlier definitions of elevated
symptoms of anxiety and depression [19], we created four groups based on baseline scores on
the HADS-A and HADS-D subscales: (i) non-anxious and non-depressed (HADS-A<8 and
HADS-D<8); (ii) anxiety symptoms only (HADS-A8 and HADS-D<8); (iii) depressive
symptoms only (HADS-A<8 and HADS-D8); and (iv) both anxiety and depressive symp-
toms (HADS-A8 and HADS-D8). To compare baseline differences in demographic and
clinical characteristics between the four groups, we used the analysis of variance (ANOVA) F
test for continuous variables and the X2 test for categorical variables. Three planned compari-
sons were performed in case of statistically significant overall results, comparing the depressed-
only, anxious-only and comorbid group with the non-anxious and non-depressed group as the
reference group. The log-rank test was used for an overall comparison of survival curves for the
four groups (visualized with Kaplan-Meier curves).
A hierarchical Cox regression analysis was then used to examine whether group status
(using the group without anxiety and depressive symptoms as the reference category) was asso-
ciated with increased mortality risk in an unadjusted analysis; (i) after adjustment for the
demographic variables age (continuous), male sex (no or yes), level of education (high or low),
and living alone (no or yes) (model 1); (ii) after adjustment for demographic variables and
HbA1c (model 2); and (iii) after additional adjustment for the presence of any cardiovascular
disease or microvascular complications (model 3).
We compared those who completed the HADS-A and HADS-D with those who did not
(fewer than 5 items), with regard to demographics and clinical variables. Furthermore, to assess
the validity of the findings, we examined whether those not completing either the HADS-A or
HADS-D had increased mortality risk. Cox regression analyses were used, unadjusted and with
adjustments (model 3).
We conducted additional sensitivity analyses with a higher cut-off point ( 11) on either or
both of the sub-scales to indicate moderate-severe symptomatology or clinically significant dis-
order [17].
Results
At baseline in the total sample (n = 948), mean age was 67 (SD 12) years (range 20–90 years)
and 49% were men. Mean HbA1c level was 61mmol/mol (SD 19) (i.e. 7.7% (SD 1.7)). Cardio-
vascular disease and microvascular complications were present in 27% and 33% of participants,
respectively. Seventy-three percent of the sample (n = 691/948) did not have elevated anxiety
or depressive symptoms, 8% (n = 77) had elevated anxiety symptoms only, 9% (n = 87) had ele-
vated depressive symptoms only, and 10% (n = 93) had both. When comparing these four
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groups with respect to demographic and clinical characteristics, significant overall differences
were found for age, HbA1c level and eye problems due to diabetes (Table 1). Planned compari-
sons were performed for these variables with the non-anxious and non-depressed (HADS-A
<8 and HADS-D<8) as the reference group. Those with elevated anxiety symptoms only had
lower HbA1c levels (p<0.001); those with elevated depressive symptoms only were older
(p<0.001) and those with both elevated anxiety and depressive symptoms had more eye prob-
lems due to diabetes (p<0.001) compared with individuals in the reference group (Table 1).
After a mean follow-up of 12 years (SD 5.1, range 0–17), 541 people had died (57%). The
survival curves for the four groups differed significantly (p<0.001) (Fig 2). The proportional
hazards assumption was satisfied (with the correlation between the Schoenfeld residuals and
ranked survival time ranging between r = -0.001 and -0.02 for the three comparisons, all non-
significant). Crude survival analyses for these three comparisons showed that compared to the
reference group of people with neither elevated anxiety nor depressive symptoms, the mortality
risk was decreased for participants with elevated anxiety symptoms only (HR 0.66, 95% CI
0.46–0.96) (p = 0.03), and increased for participants with elevated depressive symptoms only
(HR 1.59, 95% CI 1.21–2.09) (p = 0.001) (Table 2). Mortality risk did not differ between the
Table 1. Baseline characteristics of the study population (insulin naïve people with Type 2 diabetes), stratified by HADS-Anxiety and HADS-De-
pression subgroups.
Characteristics HADS-A <8 HADS-A8 HADS-A <8 HADS-A8 Overall
and and and and test
% (n) Number HADS-D <8 HADS-D <8 HADS-D8 HADS-D8 p-value*
n = 948 missing n = 691 n = 77 n = 87 n = 93
Sociodemographic characteristics
Age (years), mean (SD) 67 (12) 0 67 (12) 64 (14) 71 (10)** 65 (12) <0.001
Male sex, % (n) 49 (466) 0 50 (348) 39 (30) 52 (45) 46 (43) 0.25
Living alone, % (n) 39 (372) 3 41 (282) 36 (28) 31 (27) 38 (35) 0.30
Low education % (n) 65 (564) 82 64 (404) 63 (46) 70 (53) 73 (61) 0.27
Glycaemic control, mean (SD)
HbA1c, % units (NGSP units) 7.7 (1.7) 43 7.8 (1.7) 7.0 (1.3)** 7.8 (1.6) 7.5 (1.4) <0.001
HbA1c, mmol/mol (IFCCU) 61 (19) 43 62 (19) 53 (14) 62 (17) 58 (15)
Macrovascular complications, % (n)
Self-reported stroke a 6 (55) 35 5 (33) 8 (6) 11 (9) 8 (7) 0.09
Self-reported myocardial infarction a 12 (111) 21 11 (75) 11 (8) 17 (14) 15 (14) 0.35
Self-reported angina pectoris a 18 (167) 26 18 (118) 18 (13) 18 (15) 23 (21) 0.67
Any cardiovascular disease b 27 (250) 22 26 (173) 27 (20) 35 (30) 29 (27) 0.28
Microvascular complications, % (n)
Microalbuminuria 23(237) 87 24 (151) 24 (17) 24 (19) 18 (15) 0.62
Eye problems due to diabetes a 9 (67) 165 7 (38) 10 (6) 11 (8) 21 (15)** <0.001
Any microvascular complication b 33 (303) 173 31 (179) 34 (21) 37 (26) 36 (26) 0.68
HADS—A, mean score, (SD) 4.2 (3.7) 2.7 (2.1) 9.6 (2.2) 3.9 (2.0) 11.7 (2.8)
HADS—D, mean score, (SD) 4.5 (3.4) 3.1 (2.2) 5.3 (1.8) 9.2 (1.7) 10.6 (2.4)
a Stroke, myocardial infarction, angina pectoris and eye problems due to diabetes are self-reported.
b All medical comorbid conditions were combined into two composite disease measures: any cardiovascular disease (stroke, myocardial infarction and/or
angina pectoris) and any microvascular complications (eye problems due to diabetes and/or microalbuminuria).
*Analysis of variance (ANOVA) F test for continuous data and X2 test for categorical data.
**Indicate p values < 0.001 in planned comparisons performed for variables with overall statistically signiﬁcant results (p <0.05), with HADS-A <8 and
HADS-D <8 as the reference group.
doi:10.1371/journal.pone.0160861.t001
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Fig 2. Kaplan-Meier curve for mortality comparing HADS-Anxiety and HADS-Depression subgroups.
doi:10.1371/journal.pone.0160861.g002
Table 2. Univariable andmultivariable Cox proportional hazardsmodels for the association between baseline HADS-Anxiety and HADS-Depres-
sion subgroups and all-causemortality.
Deaths (n) Unadjusted HR (CI) Model 1 HR (CI) Model 2 HR (CI) Model 3 HR (CI)
n = 884 a n = 884 n = 884 n = 884
HADS- No Anxiety or depressive symptoms (scores <8) 392 Reference a Reference a Reference a Reference a
Only HADS-Anxiety score8 32 0.66 (0.46–0.96) 0.68 (0.47–0.99) 0.73 (0.50–1.07) 0.69 (0.47–1.10)
Only HADS-Depression score8 62 1.59 (1.21–2.09) 1.41 (1.07–1.89) 1.45 (1.10–1.92) 1.39 (1.05–1.84)
HADS- Anxiety and depressive symptoms (scores8) 55 1.06 (0.79–1.41) 1.30 (0.97–1.74) 1.35 (1.01–1.81) 1.30 (0.96–1.74)
Age (years) 1.10 (1.09–1.11) 1.11 (1.09–1.12) 1.11 (1.09–1.12) 1.10 (1.09–1.12)
Male sex 1.08 (0.91–1.28) 1.61 (1.33–1.95) 1.61 (1.32–1.95) 1.44 (1.19–1.75)
Low educationb 2.05 (1.65–2.54) 1.11 (0.88–1.40) 1.04 (0.74–1.46) 1.11 (0.88–1.40)
Living alone 1.50 (1.26–1.79) 1.12 (0.93–1.35) 1.13 (0.93–1.36) 1.13 (0.94–1.37)
HbA1c 1.09 (1.05–1.15) 1.08 (1.03–1.14) 1.08 (1.02–1.13)
Any cardiovascular disease c 2.09 (1.75–2.51) 1.39 (1.15–1.67)
Any microvascular complications b,d 1.93 (1.60–2.33) 1.35 (1.11–1.65)
Cox regression analysis was used to examine whether group status was associated with increased mortality risk in an unadjusted analysis; after adjustment
for demographics (model 1); after adjustment for demographics and HbA1c (model 2); and after adjustment for demographics, HbA1c, and the presence of
any cardiovascular disease or microvascular complication (model 3). Data are hazard ratios (HR) with 95% CI.
a Reference category.
b Missing values entered as separate category.
c Self-reported stroke, myocardial infarction and/or angina pectoris, as reported at baseline.
d Albumin/creatinine ratio >3.0 mg/mmol in at least two of the three urine samples was used to deﬁne microalbuminuria. Eye problems caused by diabetes
and/or microalbuminuria were combined into a composite measure of any microvascular complication.
doi:10.1371/journal.pone.0160861.t002
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reference group and participants with co-morbid elevated anxiety and depressive symptoms
(HR 1.06, 95% CI 0.79–1.41) (p = 0.58). Adjustment for demographic variables gave similar
results for all three comparisons (Model 1; Table 2). However, after further adjustment for
HbA1c levels, the HR for having elevated anxiety symptoms only was attenuated, changing
from 0.66 to 0.73, and was no longer statistically significant (HR 0.73, 95% CI 0.50–1.07)
(Model 2; p = 0.11). In the fully adjusted Model 3, persons with elevated depressive symptoms
only had an increased mortality risk compared to the reference group (HR 1.39, 95% CI 1.05–
1.84) (p = 0.02).
Some individuals did not complete either the HADS-A (15%) or HADS-D (10%) subscale,
or neither. Those not completing either scale were older, more likely to be women, to have
lower education, more cardiovascular disease and microvascular complications. Those not
completing the HADS-D were more likely to live alone. Non-responders on HADS-A had an
increased mortality risk compared to responders in the unadjusted analysis (HR 1.92, 95% CI
1.59–2.32) (p<0.001) and in the fully adjusted Model 3 (HR 1.42, 95% CI 1.42–1.76) (p =
0.02). Non-responders on HADS-D had an increased mortality risk compared to responders in
the unadjusted analysis (HR 2.28, 95% CI 1.76–2.78) (p<0.001) and in the fully adjusted
Model 3 (HR 1.63, 95% CI 1.28–2.10) (p<0.001).
The results from the sensitivity analysis with groups defined by HADS 11 were analogous
to our results for HADS 8. Compared to the reference group (n = 790), we observed an
increased mortality rate among participants with elevated depression symptoms only (n = 30)
(HR 1.36, 95% CI 0.88–2.11) (model 3). Probably due to a lack of power, this association was
not significant. The mortality rate did also not differ statistically between the reference group
and participants with elevated anxiety symptoms only (n = 39) (HR 0.85, 95% CI 0.52–1.39)
and those with co-morbid elevated anxiety and depressive symptoms (n = 25) (HR 1.60, 95%
CI 0.97–2.64).
Discussion
In this 17-year follow-up study of 948 people with Type 2 diabetes not using insulin, baseline
depression only (defined as a high level of depressive symptoms, without a co-morbid high
level of anxiety symptoms) was associated with a 39% increased mortality risk after adjustment
for demographics, HbA1c, and comorbidities. In contrast, anxiety only (defined as a high level
of anxiety symptoms, without a co-morbid high level of depressive symptoms) was associated
with a 34% decreased mortality risk in unadjusted analysis. However, this association was
attenuated to a 27% and no longer statistically significant reduced risk after adjustment for dif-
ferences in demographics and baseline HbA1c. Having both elevated anxiety and depression
symptoms was not associated with increased or decreased mortality risk.
Our study is the first to investigate the associations between increased baseline symptom
levels of anxiety, depression (and their co-morbidity) and subsequent mortality in a large com-
munity-based population of people with insulin naïve Type 2 diabetes. The finding that partic-
ularly depression is associated with increased mortality rates is in line with results of a meta-
analysis which showed that depression was associated with a 46% higher mortality rate in per-
sons with diabetes [8]. Cuijpers et al [21] found comparable pooled risk ratios for depression
with 52% higher mortality rates both in general communities and in clinical samples [21]. Gen-
eral communities included relatively healthy samples and specific clinic patient samples with
heart disease, cancer and kidney disease [21]. However, these studies did not examine whether
the relation between depression and mortality was less pronounced in those with co-morbid
anxiety.
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Longitudinal studies focusing on the relation between anxiety and health outcomes are lack-
ing in people with Type 2 diabetes. In this follow-up study, reporting elevated anxiety symp-
toms only was associated with a decreased mortality risk, partly explained by more optimal
levels of HbA1c in those reporting elevated anxiety symptoms. Two recent cross-sectional stud-
ies among people with Type 1 diabetes investigated the association between anxiety and HbA1c
levels [22, 23]. The results in the study of Strandberg [22] showed no significant association
between levels of anxiety and HbA1c. However, results in the study of Anderbro [23] showed a
strong relationship between fear of hypoglycemia, other diabetes-related fears, and non-diabe-
tes-related types of anxiety (measured by HADS). Moreover, elevated anxiety symptoms were
associated with a more favorable HbA1c. Similarly in our study, participants with elevated anxi-
ety symptoms only had lower HbA1c levels compared with individuals with no elevated level of
anxiety or depressive symptoms. In contrast to participants with Type 1 diabetes in the study
of Anderbro [23] participants in our study did not use insulin at baseline. Even though path-
ways may differ between people with Type 1 and Type 2 diabetes (e.g. different treatment ther-
apies and age differences at onset), the prevalence of elevated anxiety symptoms is similar in
people with Type 1 and Type 2 diabetes [4]. One explanation for our finding that having more
anxiety symptoms was associated with a more favorable HbA1c may be that anxious persons
with diabetes are more cautious about their blood glucose level and worry about diabetes-
related complications such as macro- and microvascular complications. Also, anxious people
with insulin-naïve Type 2 diabetes more often fear hypoglycemia, insulin injections or blood
glucose self-testing, a fear which has shown to be a barrier to insulin treatment in previous
studies [24, 25]. Previously, we found that elevated levels of anxiety symptoms were associated
with a later initiation of insulin, which appeared to be partly explained by better glycemic con-
trol in the anxious group, while elevated depressive symptoms were not. Persons with both ele-
vated levels of anxiety and depression were also less likely to start insulin therapy [26]. In a
longitudinal Dutch study, depression was not associated with initiation of insulin therapy in
people with type 2 diabetes [27]. Other studies have found that insulin treatment is associated
with increased mortality rates [28] and it is possible that during this follow-up HbA1c levels
increased and people subsequently started with insulin treatment which is associated with a
worse prognosis or more advanced disease. Treatment adherence may be a mediator into the
association between elevated anxiety symptoms and lower HbA1c levels. In this case, elevated
anxiety scores might be a marker for a dedicated attitude towards minimizing health risks. It
could be speculated that better treatment adherence is more often adopted as coping style in
anxious people compared to other participants with less anxiety [29]. Treatment adherence
may therefore explain the better glycemic outcome and subsequent better survival rates.
Furthermore, we found that having elevated symptoms of both anxiety and depression was
not associated with an increased mortality rate. Lou et al. [30] found different results in a large
study among 7,787 patients with chronic obstructive lung disease. In their study, depression
and anxiety had an additive effect on mortality rates. In the WISE study [31], however, depres-
sion scores were significant predictors of CVD events among women with low anxiety scores
(hazard ratio 2.3), but not among women with higher levels of anxiety (hazard ratio 0.99). This
suggests a health-protective role for anxiety, with anxiety counteracting the adverse health
effects of depression. Similarly, in the present study, decreased mortality was observed among
people with elevated anxiety symptoms. However, this was in part explained by lower HbA1c
levels.
Our study has several strengths. We have studied anxiety and depression as risk factors
early in the course of the disease by including the large, relatively homogenous sample of insu-
lin naïve people with Type 2 diabetes who were followed for a relatively long period with mor-
tality as the endpoint. At the same time, this is also a limitation, as we could not compare our
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sample to people using insulin. However, it was our a priori aim to test depressive symptoms as
a risk factor for mortality, with depression being measured in an early, relatively uncomplicated
stage of diabetes. Depression may be a consequence of complications of diabetes, which again
is associated with increased mortality risk, but this was not the focus of the paper. We therefore
requested data from participants with type 2 diabetes who were insulin-naïve at baseline and
data from participants who using insulin at baseline are thus not available to us. Hence, we do
not have the possibility to re-run the analysis including those using insulin. It is a strength is
that the self-reported assessments used do not include somatic symptoms of depression or anx-
iety thus diminishing the effect of somatic illness such as e.g. diabetes. On the other hand,
assessment of depression and anxiety symptoms was by means of a self-report measure, while a
psychiatric diagnostic interview is regarded as the gold standard for assessing mood and anxi-
ety disorders. We are aware of the fact that the validity of the HADS questionnaire has been
the subject of a recent debate. Coyne et al [32] stated that the HADS has no reliable, generalisa-
ble latent structure and questioned its continued use as a screening and assessment instrument
for major depression and anxiety. However, Norton et al [33] stated in their response that
these limitations are not unique for the HADS, other depression screening tools suffer from the
same problems. In addition, other study limitations should be discussed. First, we used self-
reported diabetes, which may induce selection bias, since people with anxiety may be less likely
to have (mild) undetected diabetes. Second, we have no information on possible changes in
health behaviours and treatment of diabetes during the follow-up period. We have only mea-
surements of anxiety and depressive symptoms at baseline and therefore we do not know the
trajectories in the follow-up. However, the study of Nefs [34] has shown that a history of
depression is the main risk factor for depression later in life. Once present, depression often
becomes a chronic/recurrent condition in this group. Third, non-responders on the HADS
questionnaire reported lower education, more self-reported cardiovascular disease and self-
reported eye problems due to diabetes and had increased mortality risk, corresponding to
results from other studies [35]. Fourth, analyses might be underpowered due to due to small
numbers of participants in the groups (anxiety symptoms only (HADS-A8 and HADS-D
<8); depressive symptoms only (HADS-A<8 and HADS-D>8); and both anxiety and depres-
sive symptoms (HADS-A8 and HADS-D8)). Finally, we could not take into account neu-
ropathy in the analysis, as we do not have these clinical data.
In sum, in a cohort of insulin-naïve participants with Type 2 diabetes followed over a period
of 17 years, an elevated level of depressive symptoms (without elevated anxiety symptoms) was
associated with a 39% increased mortality risk. A similar association was not observed among
people with elevated anxiety symptoms only. While decreased mortality was observed in this
group, it was in part explained by lower HbA1c levels. This may be interpreted as lending
weight to a hypothesis of elevated levels of anxiety symptoms leading to behavior that counter-
act the adverse health effects of Type 2 diabetes. This hypothesis needs further investigations in
future research.
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